Positron Emission Tomography (PET) Radiotracer Market Forecast 2026–2030 Highlighting Expansion Across Industries
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Positron Emission Tomography (PET) Radiotracer Market Expected To Scale Between 2026 And 2030?
The positron emission tomography (pet) radiotracer market size has seen significant growth in recent years. It is anticipated to increase from $2.54 billion in 2025 to $2.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical expansion can be linked to several factors, including a rise in cancer diagnosis rates, the expansion of nuclear medicine facilities, the well-established utilization of FDG-based imaging, the presence of cyclotron infrastructure, and the overall growth in diagnostic imaging services.
The positron emission tomography (pet) radiotracer market size is anticipated to experience substantial expansion in the coming years. This market is projected to reach $3.95 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. Key drivers of this growth during the forecast period include an escalating demand for precise diagnostic tools, increased capital allocation towards radiopharmaceutical research and development, the broadening scope of theranostics applications, greater integration of PET imaging in neurological and cardiovascular diagnostics, and a rise in regulatory clearances for novel tracers. Significant trends expected over the forecast horizon encompass the accelerated creation of target-specific radiotracers, a surge in PET imaging utilization for oncology diagnostics, the expanding application of new isotopes beyond FDG, the proliferation of personalized nuclear medicine applications, and a heightened emphasis on producing radiotracers with short half-lives.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Shaping The Positron Emission Tomography (PET) Radiotracer Market Landscape?
A rise in infectious disease cases is anticipated to drive the expansion of the positron emission tomography (PET) radiotracer market in the coming period. These diseases are defined as conditions resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites. Factors contributing to the increasing incidence of infectious diseases include climate change, urbanization, globalization, antibiotic resistance, and shifts in human behavior, all of which aid pathogen dissemination. Positron emission tomography (PET) radiotracers assist in managing infectious diseases through their ability to visualize metabolic activity and inflammation, thereby facilitating infection detection, evaluating treatment efficacy, and distinguishing between infectious and non-infectious states, ultimately leading to improved patient results. As an illustration, a report released by the UK Health Security Agency, a UK-based government body, indicated in February 2024 that tuberculosis (TB) cases in England saw a 10.7% rise in 2023, reaching 4,850 cases from 4,380 reported in 2022. Consequently, the growing occurrence of infectious diseases is fueling the expansion of the positron emission tomography (PET) radiotracer market.
Which Segment Types Are Examined In The Positron Emission Tomography (PET) Radiotracer Market Segment Study?
The positron emission tomography (pet) radiotracer market covered in this report is segmented –
1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), Other Radiotracer Types
2) By Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By F-18 (Fluorodeoxyglucose 18): F-18 FDG (Fluorodeoxyglucose), F-18 Fluoroethyltyrosine (FET), F-18 Florbetapir (Amyloid PET Imaging)
2) By Ga-68 (Fibroblast Activation Protein Inhibitor): Ga-68 Dotatate (Neuroendocrine Tumor Imaging), Ga-68 PSMA (Prostate-Specific Membrane Antigen Imaging), Ga-68 FAPI (Fibroblast Activation Protein Inhibitor Imaging)
3) By Other Radiotracer Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Rb-82 (Rubidium-82), I-124 (Iodine-124)
What Market Trends Are Affecting The Positron Emission Tomography (PET) Radiotracer Market?
Leading firms within the positron emission tomography (PET) radiotracer market are concentrating their efforts on creating sophisticated diagnostic options, including positron emission tomography imaging agents, with the goal of improving cancer identification and enhancing patient results. A PET imaging agent is defined as a radioactive compound utilized for visualizing and quantifying biological activities within the body during PET scans. As an illustration, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canadian radiopharmaceutical firm, introduced Illuccix, also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada. This product serves as a prostate cancer imaging agent specifically developed for detecting metastatic prostate cancer. This particular diagnostic instrument proves beneficial for clinicians in pinpointing metastatic disease and assisting with patient management choices. Its application is recommended for patients with suspected metastasis who are eligible for initial definitive treatment, and also for individuals with suspected recurrence, evidenced by elevated serum prostate-specific antigen (PSA) levels.
Which Players Are Part Of The Competitive Landscape Of The Positron Emission Tomography (PET) Radiotracer Market?
Major companies operating in the positron emission tomography (pet) radiotracer market are Cardinal Health Inc., GE Healthcare Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., ImaginAb Inc., Radiomedix Inc., Curium Pharma, Blue Earth Diagnostics Ltd., Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals Limited, PETNET Solutions Inc., Piramal Imaging
Get The Full Positron Emission Tomography (PET) Radiotracer Market Report:
Which Region Dominates The Positron Emission Tomography (PET) Radiotracer Market By Market Share?
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) radiotracer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Positron Emission Tomography (PET) Radiotracer Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Positron Emission Tomography (PET) Radiotracer Market 2026, By The Business Research Company
Poc Medical Imaging Market Report 2026
https://www.thebusinessresearchcompany.com/report/poc-medical-imaging-global-market-report
Veterinary Imaging Market Report 2026
https://www.thebusinessresearchcompany.com/report/veterinary-imaging-global-market-report
Pet Tech Market Report 2026
https://www.thebusinessresearchcompany.com/report/pet-tech-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
